Skip to main content
SpringerLink
Log in

Current and Future Treatments of Multiple Sclerosis

  • Chapter
  • First Online:
Multiple Sclerosis Immunology

Abstract

For many years, treatment of multiple sclerosis (MS), as the most common, disabling neurological condition in young adults in the developed world has been hampered by a lack of understanding of its initiation and progression. However, accelerating progress in MS research on several fronts has led to numerous clinical trials with a range of drugs and therapeutic principles. The vast majority of these therapeutics targets components of the immune system, as pathological, immunologic, and genetic studies point to the immune system as the primary driver of MS. While some of these drugs failed to show efficacy, others have revealed devastating side effects, and again others have proven to be beneficial. They have all shed more light on the pathogenesis of MS and contributed substantially to the understanding of this heterogeneous disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Assche G Van, Ranst M Van, Sciot R et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 353:362–368

    Article  PubMed  Google Scholar 

  • Barkhof F, Simon JH, Fazekas F et al (2011) MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol 8:13–21

    Article  PubMed  Google Scholar 

  • Bar-Or A, Fawaz L, Fan B et al (2010) Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 67:452–461

    Article  PubMed  CAS  Google Scholar 

  • Berger JR (2011) The basis for modeling progressive multifocal leukoencephalopathy pathogenesis. Curr Opin Neurol 24:262–267

    Article  PubMed  CAS  Google Scholar 

  • Bielekova B, Richert N, Howard T et al (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 101:8705–8

    Article  PubMed  CAS  Google Scholar 

  • Bielekova B, Richert N, Herman ML et al (2011) Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 77:1877–86

    Article  PubMed  CAS  Google Scholar 

  • Bisteau M, Devos G, Brucher JM, Gonsette RE (1989) Prevention of subacute experimental allergic encephalomyelitis in guinea-pigs with desferrioxamine, isoprinosine and mitoxantrone. Elsevier Science Publ B V, Amsterdam

    Google Scholar 

  • Calabresi PA, Giovannoni G, Confavreux C et al (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69:1391–403

    Article  PubMed  CAS  Google Scholar 

  • Carson KR, Focosi D, Major EO et al (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10:816–24

    Article  PubMed  CAS  Google Scholar 

  • Cohen BA, Mikol DD (2004) Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 63:28–32

    Article  Google Scholar 

  • Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415

    Article  PubMed  CAS  Google Scholar 

  • Coles AJ, Compston DA, Selmaj KW et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359:1786–801

    Article  PubMed  Google Scholar 

  • Colorado RA, Shukla K, Zhou Y, Wolinsky JS, Narayana PA (2012) Multi-task functional MRI in multiple sclerosis patients without clinical disability. NeuroImage 59:573–81

    Article  PubMed  Google Scholar 

  • Comabella M, Craig DW, Morcillo-Suarez C et al (2009a) Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 66:972–978

    Article  Google Scholar 

  • Comabella M, Rio J, Espejo C et al (2009b) Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin Immunol 130:145–150

    Article  CAS  Google Scholar 

  • Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290–297

    Article  PubMed  CAS  Google Scholar 

  • Comi G, Pulizzi A, Rovaris M et al (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371:2085–2092

    Article  PubMed  CAS  Google Scholar 

  • Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374:1503–1511

    Article  PubMed  CAS  Google Scholar 

  • Comi G, Jeffery D, Kappos L et al (2012) Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 366:1000–109

    Article  PubMed  CAS  Google Scholar 

  • Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502–1517

    Article  PubMed  CAS  Google Scholar 

  • Connick P, Kolappan M, Crawley C et al (2012) Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 11:150–156

    Article  PubMed  Google Scholar 

  • Cotte S, Ahsen N von, Kruse N et al (2009) ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 132:2517–2530

    Article  PubMed  CAS  Google Scholar 

  • Deloire MS, Ruet A, Hamel D, Bonnet M, Dousset V, Brochet B (2011) MRI predictors of cognitive outcome in early multiple sclerosis. Neurology 76:1161–1167

    Article  PubMed  CAS  Google Scholar 

  • Filippi M, Rocca MA, Benedict RH et al (2010) The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology 75:2121–128

    Article  PubMed  CAS  Google Scholar 

  • Filippi M, Rovaris M, Inglese M et al (2004) Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 364:1489–1496

    Article  PubMed  CAS  Google Scholar 

  • Fleischmann RM (2009) Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 60:3225–3228

    Article  PubMed  CAS  Google Scholar 

  • Friese MA, Craner MJ, Etzensperger R et al (2007) Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med 13:1483–1489

    Article  PubMed  CAS  Google Scholar 

  • Fugger L, Friese MA, Bell JI (2009) From genes to function: the next challenge to understanding multiple sclerosis. Nature Rev Immunol 9:408–417

    Article  CAS  Google Scholar 

  • Ghoreschi K, Bruck J, Kellerer C et al (2011) Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208:2291–2303

    Article  PubMed  CAS  Google Scholar 

  • Gonsette RE, Demonty L (1990) Immunosuppression with mitoxantrone in multiple sclerosis A pilot study for 2 years in 22 patients. Neurology 40:261

    Article  Google Scholar 

  • Gorelik L, Lerner M, Bixler S et al (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295–303

    Article  PubMed  Google Scholar 

  • Gross R, Healy BC, Cepok S et al (2011) Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol 233:168–174

    Article  PubMed  CAS  Google Scholar 

  • Group PS (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352:1498–1504

    Article  Google Scholar 

  • Group TIMSS (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB multiple sclerosis study group. Neurology 43:655–661

    Article  Google Scholar 

  • Hartung HP, Gonsette R, Konig N et al (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360:2018–2025

    Article  PubMed  Google Scholar 

  • Hauser SL, Dawson DM, Lehrich JR et al (1983) Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308:173–180

    Article  PubMed  CAS  Google Scholar 

  • Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688

    Article  PubMed  CAS  Google Scholar 

  • Havrdova E, Galetta S, Hutchinson M et al (2009a) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol 2009 8:254–260

    Article  Google Scholar 

  • Havrdova E, Zivadinov R, Krasensky J et al (2009b) Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler 15:965–976

    Article  CAS  Google Scholar 

  • Hawker K, O’Connor P, Freedman MS et al (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66:460–471

    Article  PubMed  CAS  Google Scholar 

  • Hoffmann S, Cepok S, Grummel V et al (2008) HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 83:219–227 www.Biogenidec.com

    Article  PubMed  CAS  Google Scholar 

  • Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG). Ann Neurol 39:285–294

    Article  PubMed  CAS  Google Scholar 

  • Jager PL De, Jia XM, Wang J et al (2009) Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1 A as new multiple sclerosis susceptibility loci. Nat Genet 41:776–782

    Article  PubMed  CAS  Google Scholar 

  • Jeffery DR, Chepuri N, Durden D, Burdette J (2005) A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 11:296–301

    Article  PubMed  CAS  Google Scholar 

  • Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group. Neurology 1995 45:1268–1276

    Article  PubMed  CAS  Google Scholar 

  • Jones JL, Phuah CL, Cox AL et al (2009) IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1 H). J Clin Invest 119:2052–2061

    PubMed  CAS  Google Scholar 

  • Kappos L, Antel J, Comi G et al (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124–1140

    Article  PubMed  CAS  Google Scholar 

  • Kappos L, Gold R, Miller DH et al (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372:1463–1472

    Article  PubMed  CAS  Google Scholar 

  • Kappos L, Freedman MS, Polman CH et al (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8:987–97

    Article  PubMed  CAS  Google Scholar 

  • Kappos L, Radue EW, O’Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401

    Article  PubMed  CAS  Google Scholar 

  • Kappos L, Li D, Calabresi PA et al (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378:1779–1787

    Article  CAS  Google Scholar 

  • Khatri B, Barkhof F, Comi G et al (2011) Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 10:520–529

    Article  PubMed  CAS  Google Scholar 

  • Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O’Connor PW, Simon JH (2012) Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the controlled high-risk avonex multiple sclerosis prevention study in ongoing neurological surveillance. Arch Neurol 69(2):183–190

    Article  PubMed  Google Scholar 

  • Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369–374

    Article  PubMed  CAS  Google Scholar 

  • Lalive PH, Neuhaus O, Benkhoucha M et al (2011) Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 25:401–414

    Article  PubMed  CAS  Google Scholar 

  • Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375–381

    Article  PubMed  CAS  Google Scholar 

  • Le Page E, Leray E, Edan G (2011) Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler 17:867–875

    Article  PubMed  CAS  Google Scholar 

  • Liguori M, Healy BC, Glanz BI et al (2011) HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. Genes Immun 12:183–190

    Article  PubMed  CAS  Google Scholar 

  • Linda H, Heijne A von, Major EO et al (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361:1081–1087

    Article  PubMed  CAS  Google Scholar 

  • Linker RA, Lee DH, Ryan S et al (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134:678–692

    Article  PubMed  Google Scholar 

  • Lucchinetti CF, Popescu BF, Bunyan RF et al (2011) Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365:2188–197

    Article  PubMed  CAS  Google Scholar 

  • Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS, CombiRx Investigators (2013) Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 73(3):327–340. doi:10.1002/ana.23863

    Google Scholar 

  • Major EO (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Ann Rev Med 61:35–47

    Article  PubMed  CAS  Google Scholar 

  • Mandala S, Hajdu R, Bergstrom J et al (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346–349

    Article  PubMed  CAS  Google Scholar 

  • Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW (2010) Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology 74:1463–1470

    Article  PubMed  CAS  Google Scholar 

  • Marshall LJ, Dunham L, Major EO (2010) Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity. J Gen Virol 91:3042–3052

    Article  PubMed  CAS  Google Scholar 

  • Merkler D, Metz GA, Raineteau O, Dietz V, Schwab ME, Fouad K (2001) Locomotor recovery in spinal cord-injured rats treated with an antibody neutralizing the myelin-associated neurite growth inhibitor Nogo-A. J Neurosci 21:3665–3673

    PubMed  CAS  Google Scholar 

  • Mi S, Hu B, Hahm K et al (2007) LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 13:1228–1233

    Article  PubMed  CAS  Google Scholar 

  • Mikol DD, Barkhof F, Chang P et al (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7:903–914

    Article  PubMed  CAS  Google Scholar 

  • Millac P, Miller H (1969) Cyclophosphamide in multiple sclerosis. Lancet 1:783

    Article  PubMed  CAS  Google Scholar 

  • Miller DH, Weber T, Grove R et al (2012) Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 11(2):131–139

    Article  PubMed  CAS  Google Scholar 

  • Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP (2008) FTY720 modulates human oligodendrocyte progenitor process extension and survival. Annal Neurol 63:61–71

    Article  PubMed  CAS  Google Scholar 

  • Moll NM, Rietsch AM, Thomas S et al (2011) Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann Neurol 70:764–73

    Article  PubMed  Google Scholar 

  • Moreau T, Thorpe J, Miller D et al (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344:298–301

    Article  PubMed  CAS  Google Scholar 

  • Noseworthy JH, Wolinsky JS, Lublin FD et al (2000) Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 54:1726–1733

    Article  PubMed  CAS  Google Scholar 

  • O’Connor PW, Li D, Freedman MS et al (2006) A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66:894–900

    Article  PubMed  CAS  Google Scholar 

  • O’Connor P, Filippi M, Arnason B et al (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8:889–97

    Article  PubMed  CAS  Google Scholar 

  • O’Connor P, Wolinsky JS, Confavreux C et al (2011a) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365:1293–1303

    Article  Google Scholar 

  • O’Connor PW, Goodman A, Kappos L et al (2011b) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76:1858–1865

    Article  Google Scholar 

  • Oosten BW van, Barkhof F, Truyen L et al (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531–1534

    Article  PubMed  Google Scholar 

  • Paty DW, Li DK (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43:662–667

    Article  PubMed  CAS  Google Scholar 

  • Pilar MMdel, Cravens PD, Winger R et al (2008) Decrease in the numbers of dendritic cells and CD4 + T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 65:1596–1603

    Article  Google Scholar 

  • Pitt D, Boster A, Pei W et al (2010) Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol 67:812–818

    Article  PubMed  Google Scholar 

  • Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T (2005) Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64:987–991

    Article  PubMed  CAS  Google Scholar 

  • Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910

    Article  PubMed  CAS  Google Scholar 

  • Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302

    Article  PubMed  Google Scholar 

  • Popescu BF, Lucchinetti CF (2012) Pathology of demyelinating diseases. Ann Rev Pathol 7:185–217

    Article  CAS  Google Scholar 

  • Prinjha R, Moore SE, Vinson M et al (2000) Inhibitor of neurite outgrowth in humans. Nature 403:383–384

    Article  PubMed  CAS  Google Scholar 

  • Prinz M, Kalinke U (2010) New lessons about old molecules: how type I interferons shape Th1/Th17-mediated autoimmunity in the CNS. Trends Mol Med 16:379–386

    Article  PubMed  CAS  Google Scholar 

  • Prinz M, Schmidt H, Mildner A et al (2008) Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28:675–686

    Article  PubMed  CAS  Google Scholar 

  • Ravnborg M, Sorensen PS, Andersson M et al (2010) Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol 9:672–680

    Article  PubMed  CAS  Google Scholar 

  • Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923

    Article  PubMed  CAS  Google Scholar 

  • Ruiter MB de, Tomassini V, Arun T et al (2011) Acid-sensing ion channel 1 blockade preserves brain microstructural integrity in patients with multiple sclerosis. Mult Scler 17:S205

    Google Scholar 

  • Sawcer S, Hellenthal G, Pirinen M et al (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:214–219

    Article  PubMed  CAS  Google Scholar 

  • Schimrigk S, Brune N, Hellwig K et al (2006) Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Euro J Neurol 13:604–610

    Article  CAS  Google Scholar 

  • Schwab SR, Cyster JG (2007) Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 8:1295–1301

    Article  PubMed  CAS  Google Scholar 

  • Schweckendiek W (1959) [Treatment of psoriasis vulgaris]. Med Monatsschr 13:103–4

    PubMed  CAS  Google Scholar 

  • Seewann A, Kooi EJ, Roosendaal SD et al (2012) Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 78:302–308

    Article  PubMed  CAS  Google Scholar 

  • Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH (2008) Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 7:796–804

    Article  PubMed  CAS  Google Scholar 

  • Sombekke MH, Lukas C, Crusius JB et al (2009) HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch Neurol 66:1531–1536

    Article  PubMed  Google Scholar 

  • Sorensen PS, Mellgren SI, Svenningsson A et al (2009) NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 8:519–529

    Article  PubMed  CAS  Google Scholar 

  • Sorensen PS, Jensen PE, Haghikia A et al (2011a) Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler 17:1074–1078

    Article  CAS  Google Scholar 

  • Sorensen PS, Lycke J, Eralinna JP et al (2011b) Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol 10:691–701

    Article  CAS  Google Scholar 

  • Sormani MP, Li DK, Bruzzi P et al (2011) Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology 77:1684–1690

    Article  PubMed  CAS  Google Scholar 

  • Soulillou JP, Cantarovich D, Le MBetal (1990) Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 322:1175–1182

    Article  PubMed  CAS  Google Scholar 

  • Stroet A, Gold R, Chan A, Martinelli V, Straffi L, Comi G (2012) Acute myeloid leukemia in italian patients with multiple sclerosis treated with mitoxantrone. Neurology 78:933–934

    Article  PubMed  Google Scholar 

  • Thone J, Ellrichmann G, Seubert S et al (2012) Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor. Am J Pathol 180:267–274

    Article  PubMed  CAS  Google Scholar 

  • Tony HP, Burmester G, Schulze-Koops H et al (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 13:R75

    Article  PubMed  CAS  Google Scholar 

  • Treumer F, Zhu K, Glaser R, Mrowietz U (2003) Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 121:1383–1388

    Article  PubMed  CAS  Google Scholar 

  • Tubridy N, Behan PO, Capildeo R et al (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53:466–472

    Article  PubMed  CAS  Google Scholar 

  • Uccelli A, Laroni A, Freedman MS (2011) Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 10:649–656

    Article  PubMed  CAS  Google Scholar 

  • Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH (2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70:1150–1151

    Article  PubMed  CAS  Google Scholar 

  • Vermersch P, Kappos L, Gold R et al (2011) Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76:1697–1704

    Article  PubMed  CAS  Google Scholar 

  • Vincenti F, Kirkman R, Light S et al (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338:161–165

    Article  PubMed  CAS  Google Scholar 

  • Vollmer T, Panitch H, Bar-Or A et al (2008) Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 14:663–670

    Article  PubMed  CAS  Google Scholar 

  • Webster AC, Ruster LP, McGee R et al (2010) Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 1:CD003897

    PubMed  Google Scholar 

  • Weiner HL (2009) The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 65:239–248

    Article  PubMed  CAS  Google Scholar 

  • Wenning W, Haghikia A, Laubenberger J et al (2009) Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361:1075–1080

    Article  PubMed  CAS  Google Scholar 

  • Wuest SC, Edwan JH, Martin JF et al (2011) A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 17:604–609

    Article  PubMed  CAS  Google Scholar 

  • Wynn D, Kaufman M, Montalban X et al (2010) Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 9:381–390

    Article  PubMed  CAS  Google Scholar 

  • Xiong ZG, Zhu XM, Chu XP et al (2004) Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell 118:687–698

    Article  PubMed  CAS  Google Scholar 

  • Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356:63–66

    Article  PubMed  CAS  Google Scholar 

  • Yousry TA, Major EO, Ryschkewitsch C et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924–933

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, St. Josef-Hospital Bochum, Ruhr-Universität, Bochum, Germany

    Aiden Haghikia MD & Ralf Gold MD

  2. Nuffield Department of Clinical Neurosciences and MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK

    Aiden Haghikia MD

Authors
  1. Aiden Haghikia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralf Gold MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aiden Haghikia MD .

Editor information

Editors and Affiliations

  1. National Institute of Neuroscience, National Center of Neurology and Psychia, Tokyo, Japan

    Takashi Yamamura

  2. Clinical Neurology, University of Nottingham, Nottingham, United Kingdom

    Bruno Gran

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Haghikia, A., Gold, R. (2013). Current and Future Treatments of Multiple Sclerosis. In: Yamamura, T., Gran, B. (eds) Multiple Sclerosis Immunology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7953-6_17

Download citation

Publish with us

Policies and ethics

Search

Navigation